Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer

[1]  A. Broeks,et al.  An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer , 2021, Nature Medicine.

[2]  Yoon Park,et al.  TIGIT/CD226 Axis Regulates Anti-Tumor Immunity , 2021, Pharmaceuticals.

[3]  L. Zitvogel,et al.  Immunodynamics of explanted human tumors for immuno‐oncology , 2020, EMBO molecular medicine.

[4]  D. Lambrechts,et al.  A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling , 2020, Cell Research.

[5]  I. Wistuba,et al.  A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas. , 2020 .

[6]  A. Broeks,et al.  Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers , 2020, Nature Medicine.

[7]  Yulong Chen,et al.  TIGIT enhances CD4+ regulatory T‐cell response and mediates immune suppression in a murine ovarian cancer model , 2020, Cancer medicine.

[8]  S. Warming,et al.  CD96 functions as a co‐stimulatory receptor to enhance CD8+ T cell activation and effector responses , 2020, European journal of immunology.

[9]  C. Lepage,et al.  Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study , 2019, Gut.

[10]  K. Jakubowska,et al.  Tumor-infiltrating lymphocytes in primary tumors of colorectal cancer and their metastases , 2019, Experimental and therapeutic medicine.

[11]  R. Boidot,et al.  Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination , 2019, Journal of Immunotherapy for Cancer.

[12]  F. Hodi,et al.  Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade , 2019, Nature Immunology.

[13]  J. Ko,et al.  Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer , 2019, Cancer Immunology Research.

[14]  A. Debucquoy,et al.  The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients. , 2018, Cancer cell.

[15]  Yanfeng Gao,et al.  Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells , 2018, Front. Immunol..

[16]  Paul J. Hoffman,et al.  Comprehensive Integration of Single-Cell Data , 2018, Cell.

[17]  W. Dougall,et al.  TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma. , 2018, Blood.

[18]  F. Marincola,et al.  International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.

[19]  Christopher M. Jackson,et al.  TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM , 2018, Oncoimmunology.

[20]  R. Lothe,et al.  CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models , 2017, Scientific Reports.

[21]  R. Kumar,et al.  PD-1 blockade restores impaired function of ex vivo expanded CD8+ T cells and enhances apoptosis in mismatch repair deficient EpCAM+PD-L1+ cancer cells , 2017, OncoTargets and therapy.

[22]  Genevera I. Allen,et al.  TCGA2STAT: simple TCGA data access for integrated statistical analysis in R , 2016, Bioinform..

[23]  John J Miles,et al.  Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. , 2016, Cancer discovery.

[24]  T. Schell,et al.  T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients , 2016, Clinical Cancer Research.

[25]  J. Hackney,et al.  The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. , 2014, Cancer cell.

[26]  F. Souza-Fonseca-Guimaraes,et al.  The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions , 2014, Nature Immunology.

[27]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[28]  S. Rosenberg,et al.  Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy , 2013, The Journal of Immunology.

[29]  Jimmy Lin,et al.  Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.

[30]  N. Halama,et al.  Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration , 2013, Oncoimmunology.

[31]  Vijay K. Kuchroo,et al.  Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions , 2011, The Journal of Immunology.

[32]  N. Stanietsky,et al.  The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity , 2009, Proceedings of the National Academy of Sciences.

[33]  E. Kremmer,et al.  CD96 Interaction with CD155 via Its First Ig-like Domain Is Modulated by Alternative Splicing or Mutations in Distal Ig-like Domains* , 2009, Journal of Biological Chemistry.

[34]  E. Chiang,et al.  TIGIT: A Key Inhibitor of the Cancer Immunity Cycle. , 2017, Trends in immunology.

[35]  H. Clark,et al.  The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells , 2009, Nature Immunology.